Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

Circulation

Volumn 105, Issue 10, 2002, Pages 1162-1169

  Simes, R John ^a   Marschner, Ian C ^a   Hunt, David ^b   Colquhoun, David ^c   Sullivan, David ^d   Stewart, Ralph A H ^e   Hague, Wendy ^a   Keech, Anthony ^a   Thompson, Peter ^f   White, Harvey ^g   Shaw, John ^h   Tonkin, Andrew ^h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF OTAGO   (New Zealand)

^f SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^g GREEN LANE HOSPITAL   (New Zealand)

^h NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

Author keywords

Apolipoproteins; Atherosclerosis; Cholesterol; Coronary disease; Lipids

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DRUG EFFICACY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; TREATMENT OUTCOME;

ADULT; AGED; ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; ENDPOINT DETERMINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK; RISK ASSESSMENT; RISK FACTORS; TIME; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0037066048     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc1002.105136     Document Type: Article

References (24)

1. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
2. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease
3. Serum cholesterol as a prognostic factor after myocardial infarction: The Framingham study
4. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
5. Cholesterol lowering trial results in their epidemiological context
6. The value of lowering cholesterol after myocardial infarction
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
8. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
9. Regression methods of life tables (with discussion)
10. Long-term risk stratification for survivors of acute coronary syndromes: Results from the LIPID study
11. Statistical validation of intermediate endpoints for chronic diseases
12. Lowering cardiovascular risk by cholesterol reduction: Evidence from observational studies and randomized trials
13. Lipid lowering in the patient at risk: The next decade of discovery
14. Randomised trial of cholesterol-lowering therapy, of antioxidant vitamins in 20,536 people at increased risk of coronary heart disease death
15. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
16. Influence of baseline lipids on effectiveness of pravastatin in the CARE trial
17. The effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project
18. The Lipid Research Clinics Coronary Prmary Prevention Trial Results, II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
19. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
20. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
21. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol
22. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TExCAPS)
23. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction